BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 4; pp. 1253 - 1258
Main Authors Pan, Rongqing Aaron, Wang, Youzhen, Qiu, Shumei, Villalobos-Ortiz, Mariana, Ryan, Jeremy, Morris, Erick, Halilovic, Ensar, Letai, Anthony
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.04.2024
Ferrata Storti Foundation
Subjects
Antineoplastic Agents - pharmacology
Apoptosis
Cell Line, Tumor
Humans
Letter to the Editor
Peptide Fragments - pharmacology
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-bcl-2
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 23
Disclosures
Contributions
RP, EH and AL designed the research. RP, JR, YW and SQ performed the research. MV and JR contributed vital reagents. RP, YW, EH, EM and AL analyzed the data. RP wrote the original draft. RP, EM, EH and AL reviewed and edited the manuscript.
This work is supported by a NCI/NIH grant R35 CA242427 and a research agreement with Novartis A10838. RP and MV have no conflicts of interest to disclose. JR is a consultant for Zentalis Pharmaceuticals. SQ and EH are employees at and shareholders of Novartis. EM and YW were employees at and shareholders of Novartis during this work. AL is on the scientific advisory boards of Zentalis Pharmaceuticals and Flash Therapeutics. He has performed consulting for AbbVie and Boehringer-Ingelheim.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2023.283060